Nicholson Price

Learn More
Background: Interferon-β (IFNβ) has proven to be an important advance in the therapy of multiple sclerosis (MS), but optimal markers for bioactivity have not been identified. To accurately measure bioactivity in MS patients treated with IFNβ, we developed and tested a real-time reverse transcriptase (RT)-PCR assay for gene expression of MxA, an IFNβ-induced(More)
We analyze firms’ decisions to invest in incremental and radical innovation, focusing specifically on pharmaceutical research. We first develop a new measure of drug novelty that is based on the chemical similarity of new drug candidates to existing drugs. We show that drug candidates that we identify as ex-ante novel are riskier investments, in the sense(More)
6063 Background: Multidisciplinary care (MDC) has been found to improve outcomes for women with breast cancer and clinical practice guidelines recommend management in an MDC setting. Key reports about cancer control highlight the need for reform of cancer service delivery. A national demonstration project was conducted in Australia to examine approaches to(More)
  • 1